With this agreement, Cardinal Health will have exclusive US rights to distribute Lymphoseek for an initial term of five years following FDA clearance to market the product.
David Bupp, Neoprobe’s president and CEO, said: “Completing this agreement, coupled with the announcement of our recent discussions with the FDA regarding the Phase III clinical evaluation of Lymphoseek, are pivotal milestone events for Neoprobe. We believe this agreement meets our strategic objective of maximizing the long-term revenue and operating income opportunity that Lymphoseek represents for us.”